QVCAD
First FDA-approved AI/CAD system for concurrent reading of 3D Automated Breast Ultrasound (ABUS) exams
Software · On PremiseCompany source
Company profile
About QView Medical
QView Medical, Inc. is a Silicon Valley-based medical imaging company specializing in artificial intelligence solutions for breast cancer detection. The company has developed QVCAD, the first FDA-approved computer-aided detection (CAD) system specifically designed for 3D Automated Breast Ultrasound (ABUS) screening in women with dense breast tissue. The QView team brings over 20 years of experience in CAD and ABUS development, having been involved in obtaining four PMA approvals including R2 mammography CAD, R2 lung CT CAD, U-Systems somo.v ABUS, and QView QVCAD. The company's technology enables radiologists to review entire ABUS screening exams at a single glance, improving detection efficiency and accuracy. QView QVCAD works in conjunction with GE Healthcare's Invenia ABUS system and is deployed in clinical settings including breast imaging centers. The company maintains strategic partnerships with GE Healthcare and has established European distribution through Traf Intercontinental. QView Medical's mission centers on advancing breast cancer detection through AI technology, with a particular focus on addressing the challenges of screening women with dense breast tissue, who face higher cancer risks and reduced mammography effectiveness.
Company description QView Medical official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceX
Work at QView Medical?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Dense breast tissue screening
Who it serves
- Breast Imaging Clinics
- Health Systems
- Radiology Centers
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: GE Healthcare Invenia ABUS.
Geographic context
MarketsEurope · United States
Company sourceOfficial website
Company milestones
Platform expansion
November 2021: Alliance with GE Healthcare to maintain leadership in AI-powered breast cancer screening. October 2021: Joined AmIDense.com initiative for Breast Cancer Awareness Month. June 2020: European distribution agreement with Traf Intercontinational. November 2018: First joint installation with GE Healthcare Invenia ABUS at RSNA.
Partnerships
Recorded partners
- GE Healthcare
- Traf Intercontinental (European distribution)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Segmentation of malignant lesions in 3D breast ultrasound using a depth-dependent model.Medical physics · Jul 1, 2016
Computer-aided detection of breast cancers using Haar-like features in automated 3D breast ultrasound.Medical physics · Apr 1, 2015
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
QVCAD SystemP150043 · Pma · Nov 9, 2016
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved screening efficiency
Radiologists can review entire ABUS case in single glance with QVCAD
Enhanced detection for dense breast tissue
First CAD system specifically approved for screening women with dense breast tissue
Eve Wellness - San Francisco
ABUS screening exam review for breast cancer detection in women with dense breast tissue
Enables examination of entire case in a single glance, with ultrasound CAD found more critical for screening than mammography CAD
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Ralph Smathers
M.D.
06 · Company updates
Updates from QView Medical
Recent articles published on QView Medical's official website.
AI for Automated Breast Ultrasound: QView Medical’s Leadership in ABUS AI
Read on QView MedicalQView Signs European Distribution Agreement for QVCAD
Read on QView MedicalQView Announces Alliance with GE HealthCare for AI-Powered Breast Cancer Screening
Read on QView MedicalDense Breast Tissue and ABUS: What Women Should Know
Read on QView MedicalQView Showcases QVCAD for Concurrent Reading of ABUS Exams at RSNA
Read on QView Medical07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.